Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06625320 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Study acronym: RASolute 302
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv37
  2. Enrollment target: 501 to 500v36
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 460 to confirmed 501 · Site details revised at 60 of 60 sitesv35 Show 2 more changesShow less
    • Enrollment target: estimated 460 to confirmed 501
    • Site details revised at 60 of 60 sites
  4. Site contacts updated at 3 of 60 sitesv34
  5. Study sites: 58 to 60v33
Show 31 earlier versionsHide 31 earlier versions
  1. Study sites: 47 to 58v32
  2. Study sites: 39 to 47 Eligibility criteria shortened, about 1 wordv31 Show 1 more changeShow less
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 33 to 39v30
  4. Study sites: 29 to 33v29
  5. Study sites: 25 to 29v28
  6. Study sites: 22 to 25 Study title expanded, about 1 wordv27 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites: 19 to 22v26
  8. Study sites: 16 to 19v25
  9. Study sites: 15 to 16v24
  10. Site contacts updated at 2 of 15 sitesv23
  11. Study sites: 13 to 15v22
  12. Study sites: 11 to 13v21
  13. Study sites: 10 to 11v20
  14. Site contacts updated at 3 of 10 sitesv19
  15. Study sites: 9 to 10v18
  16. Study sites: 7 to 9v17
  17. Site contacts updated at 1 of 7 sitesv16
  18. Study sites: 6 to 7v15
  19. Study sites: 5 to 6v14
  20. Site contacts updated at 2 of 5 sitesv13
  21. Study sites: 4 to 5v12
  22. Site contacts updated at 1 of 4 sitesv11
  23. Site contacts updated at 2 of 4 sitesv10
  24. Study sites: 3 to 4v9
  25. Site contacts updated at 2 of 3 sitesv8
  26. Study sites: 2 to 3v7
  27. Study sites: 1 to 2 Start date changed from estimate of Oct 15, 2024 to Oct 16, 2024v6 Show 1 more changeShow less
    • Start date changed from estimate of Oct 15, 2024 to Oct 16, 2024
  28. Re-verified, no change to tracked fieldsv5
  29. Site contact updatedv4
  30. Study title shortened, about 3 wordsv3 See this version in full on ClinicalTrials.gov ↗
  31. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 30, 2024 to Oct 15, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Sep 30, 2024 to Oct 15, 2024
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Trial Details
NCT Number NCT06625320
Lead Sponsor Revolution Medicines, Inc.
Conditions Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov